Home Stock

Stock Research: United Therapeutics

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

United Therapeutics

NSQ:UTHR US91307C1027
49
  • Value
    11
  • Growth
    31
  • Safety
    Safety
    100
  • Combined
    49
  • Sentiment
    70
  • 360° View
    360° View
    49
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

United Therapeutics Corporation is a pharmaceutical company. They focus on commercial therapies for pulmonary arterial hypertension (PAH) and also have an oncology product. The company operates in the pharmaceutical industry, with products like Tyvaso DPI and Remodulin. In the last fiscal year, the company had a market cap of $13,318 million, profits of $2,568 million, and revenue of $2,877 million, with 1305 employees.

more
Strongest Rank Dividend Yield
Weakest Rank Safety
Country USA
Industry Biotechnology
Size Large
Website unither.com
Index
NASDAQ
D.J. US Health Care
S&P MIDCAP
United Therapeutics stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 27-Feb-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
11 22 n/a n/a
Growth
31 77 n/a n/a
Safety
Safety
100 89 n/a n/a
Sentiment
70 88 n/a n/a
360° View
360° View
49 88 n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
26 34 n/a n/a
Opinions Change
66 47 n/a n/a
Pro Holdings
n/a 100 n/a n/a
Market Pulse
90 93 n/a n/a
Sentiment
70 88 n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
11 22 n/a n/a
Growth
31 77 n/a n/a
Safety Safety
100 89 n/a n/a
Combined
49 74 n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
54 17 n/a n/a
Price vs. Earnings (P/E)
15 53 n/a n/a
Price vs. Book (P/B)
57 44 n/a n/a
Dividend Yield
1 1 n/a n/a
Value
11 22 n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
32 56 n/a n/a
Profit Growth
57 59 n/a n/a
Capital Growth
21 59 n/a n/a
Stock Returns
59 91 n/a n/a
Growth
31 77 n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
64 69 n/a n/a
Refinancing
89 49 n/a n/a
Liquidity
100 96 n/a n/a
Safety Safety
100 89 n/a n/a

Similar Stocks

Discover high‑ranked alternatives to United Therapeutics and broaden your portfolio horizons.

Global Payments

NYQ:GPN
Country: USA
Industry: Other Financial Services
Size: X-Large
Full Stock Analysis

Omnicom

NYQ:OMC
Country: USA
Industry: Advertising
Size: X-Large
Full Stock Analysis

Mosaic

NYQ:MOS
Country: USA
Industry: Fertilizers & Agricultural Chemicals
Size: X-Large
Full Stock Analysis

Labcorp

NYQ:LH
Country: USA
Industry: Health Care Services
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

This stock offers a high growth opportunity with safe financing and positive sentiment. It is typically expensive (low Value Rank), as investors pay a premium for high performance. It is for growth-focused investors comfortable paying a premium for a stock with strong future momentum.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews